Translational Entrepreneur
Lead Research Organisation:
University of Edinburgh
Department Name: Royal (Dick) School of Veterinary Scienc
Abstract
The University of Edinburgh and the MRC are piloting a new approach to take Edinburgh s world-leading medical science and translate this into direct benefits for patients and the local and wider community. Both commercial and non-commercial benefits are to be supported.
Technical Summary
The University of Edinburgh s College of Medicine and Veterinary Medicine, exploiting a longstanding focus on interdisciplinary research, wishes funding in part support of a pilot project to test the concept of a Translational Entrepreneur to galvanise a step-change in translation of our world-leading biomedical science (14th in World, 5th in Europe, THES, Nov 2005) into improvements in human (and animal) health.
Organisations
- University of Edinburgh, United Kingdom (Lead Research Organisation)
- Institute of Cancer Research UK (Collaboration)
- Heriot-Watt University, United Kingdom (Collaboration)
- Funky Fone Sox Company (Collaboration)
- NHS Lothian (Collaboration)
- Concept Life Sciences (Collaboration)
- Aquila Histoplex (Collaboration)
People |
ORCID iD |
| Jonathan Seckl (Principal Investigator) | |
| John Savill (Co-Investigator) |
Publications
McPherson RC
(2014)
Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4(+) T cells tolerized by peptide immunotherapy.
in eLife
Medine CN
(2013)
Developing high-fidelity hepatotoxicity models from pluripotent stem cells.
in Stem cells translational medicine
O'Connor R
(2008)
Cutting Edge: Th1 Cells Facilitate the Entry of Th17 Cells to the Central Nervous System during Experimental Autoimmune Encephalomyelitis
in The Journal of Immunology
| Description | Business in the Parliament Conference-Scotland |
| Geographic Reach | National |
| Policy Influence Type | Participation in advisory committee |
| Description | Economy Committee Scottish Parliment |
| Geographic Reach | National |
| Policy Influence Type | Gave evidence to a government review |
| Description | Holyrood Expert panel in life science business to Scottish Executive |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Participation in advisory committee |
| Description | LiSAB ( life science advisory board ) |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Participation in advisory committee |
| Impact | LiSAB is a joint industry, enterprise and government strategy team that plays a crucial role in ensuring Scotland has the best possible environment for fledgling technologies and established players alike. It fosters support and discussion between key players in the life sciences sector and those responsible for government policy-making at the very highest level. LiSAB has a very active remit; to develop and drive overall life sciences strategy in Scotland; developing an environment where ingenuity and innovation can create jobs and wealth for Scotland, as well as genuine benefits for the global community. |
| Description | Meeting with Governor Bank England |
| Geographic Reach | National |
| Policy Influence Type | Participation in a national consultation |
| Impact | Key discussion around bank finance. Clear changes in Government approach to SME lending. |
| Description | Aquila Biomedical (Regional Selective Assistance) |
| Amount | £230,000 (GBP) |
| Organisation | Government of Scotland |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2016 |
| End | 03/2018 |
| Description | BioQuarter ESCF fund NeurocentRx Pharma proposition support |
| Amount | £22,848 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2012 |
| End | 05/2013 |
| Description | BioSKAPE (Fibromed) |
| Amount | £67,000 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2012 |
| End | 03/2013 |
| Description | Confidence in Concept |
| Amount | £700,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2012 |
| End | 06/2014 |
| Description | Edinburgh BioQuarter Aquila Biomedical market |
| Amount | £10,000 (GBP) |
| Funding ID | GQ2514 |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2012 |
| End | 08/2013 |
| Description | Edinburgh BioQuarter Fibromed validation |
| Amount | £19,370 (GBP) |
| Funding ID | GQ2630 |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2012 |
| End | 09/2013 |
| Description | Edinburgh BioQuarter Funding/Edinburgh bioQuarter |
| Amount | £6,000,000 (GBP) |
| Organisation | University of Edinburgh |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2010 |
| End | 04/2015 |
| Description | Executive Director Designate ERDF Aquila Biomedical |
| Amount | £36,000 (GBP) |
| Organisation | European Commission |
| Department | European Regional Development Fund (ERDF) |
| Sector | Public |
| Country | Belgium |
| Start | 11/2011 |
| End | 08/2012 |
| Description | Executive Director Designate Fibromed CBO |
| Amount | £36,000 (GBP) |
| Organisation | European Commission |
| Department | European Regional Development Fund (ERDF) |
| Sector | Public |
| Country | Belgium |
| Start | 06/2012 |
| End | 03/2013 |
| Description | Executive Director Designate Fibromed CEO |
| Amount | £36,000 (GBP) |
| Organisation | European Commission |
| Department | European Regional Development Fund (ERDF) |
| Sector | Public |
| Country | Belgium |
| Start | 06/2012 |
| End | 03/2013 |
| Description | Executive Director Designate NeurocentRx Pharma MD |
| Amount | £36,000 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2012 |
| End | 07/2013 |
| Description | Galapagos Edinburgh Cancer Discovery Unit |
| Amount | £600,000 (GBP) |
| Organisation | Galapagos Genomics |
| Sector | Private |
| Country | Belgium |
| Start | 08/2012 |
| End | 09/2014 |
| Description | Generation Scottland Resource Access Fibromed Ltd |
| Amount | £30,000 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2012 |
| End | 12/2012 |
| Description | Graduate Internship Aquila BioMedical |
| Amount | £7,500 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2013 |
| End | 02/2014 |
| Description | Graduate Internship Aquila Biomedical |
| Amount | £7,500 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2011 |
| End | 03/2012 |
| Description | Graduate Internship Aquila Biomedical |
| Amount | £7,500 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2012 |
| End | 04/2013 |
| Description | High Growth Unit (Fibromed Products) |
| Amount | £50,000 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2016 |
| End | 12/2017 |
| Description | Initiating knowledge transfer (IKT) Edinburgh research & innovation/Edinburgh Research & Innovation |
| Amount | £7,000 (GBP) |
| Organisation | University of Edinburgh |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 12/2010 |
| End | 03/2011 |
| Description | Innovation Grant (FibromedProducts) |
| Amount | £5,000 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2016 |
| End | 12/2019 |
| Description | Innovation Grant Pain Models Aquila |
| Amount | £16,000 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2012 |
| End | 01/2013 |
| Description | Interim Management Support Fibromed |
| Amount | £8,250 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2012 |
| End | 10/2012 |
| Description | International Manager for Hire Aquila Biomedical |
| Amount | £25,000 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2012 |
| End | 08/2013 |
| Description | Investment (Neurocentrx Pharma) |
| Amount | £300,000 (GBP) |
| Organisation | Neurocentrx Pharma |
| Sector | Private |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 01/2020 |
| Description | Investment in NeurocentRx Ltd |
| Amount | £300,000 (GBP) |
| Organisation | Equity Gap |
| Sector | Private |
| Country | United Kingdom |
| Start | 02/2016 |
| End | 03/2019 |
| Description | Investor Ready Grant Aquila Biomedical |
| Amount | £10,000 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2012 |
| End | 12/2013 |
| Description | LSBAS support of diagnostic venture |
| Amount | £15,000 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2008 |
| End | 09/2008 |
| Description | LSBAS support of in vivo venture |
| Amount | £15,000 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2008 |
| End | 11/2008 |
| Description | MRC Developmental Pathway Funding Scheme (DPFS) |
| Amount | £2,000,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2009 |
| End | 03/2011 |
| Description | Marketing Grant Aquila Biomedical |
| Amount | £7,000 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2012 |
| End | 02/2013 |
| Description | NC3R MRC DPFS (Functional Optical Imaging in mice and man) |
| Amount | £100,000 (GBP) |
| Organisation | National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Neuropathic pain trial agent production |
| Amount | £30,000 (GBP) |
| Organisation | NHS Lothian |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2012 |
| End | 06/2013 |
| Description | Proof of Concept (TRPM8) |
| Amount | £400,000 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2007 |
| End | 10/2009 |
| Description | Proof of Concept support of psychiatry patents |
| Amount | £5,000 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2008 |
| End | 12/2008 |
| Description | SMART Aquila BioMedial |
| Amount | £100,000 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2013 |
| End | 12/2014 |
| Description | SMART Aquila Biomedical |
| Amount | £70,000 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2011 |
| End | 03/2012 |
| Description | Scottish Universities Life Sciences Alliance (SULSA) |
| Amount | £50,000 (GBP) |
| Organisation | Scottish Universities Life Sciences Alliance |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2009 |
| End | 03/2010 |
| Description | Tool Box for MHRA submission |
| Amount | £50,000 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2008 |
| End | 12/2008 |
| Description | undergraduate placement programme (Aquila BioMedical) |
| Amount | £14,000 (GBP) |
| Organisation | Scottish Universities Life Sciences Alliance |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 07/2016 |
| End | 07/2022 |
| Description | Aquila BioMedical -Histoplex LLP |
| Organisation | Aquila Histoplex |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The mechanism of action company Aquila Biomedical provides an established CRO laboratory and an expanding set of clients |
| Collaborator Contribution | LLP with an University team providing advanced histology testing including the first UK accredited RNAscope service. |
| Impact | support of Aquila services in autoimmune disease, immuno-oncology through testing of histology samples from model systems and the clinic, and income generation. This LLP has been successful for Aquila and Histoplex team that the LLP will be dissolved early 2017 and will formally become a division of the profitable global company. |
| Start Year | 2017 |
| Description | Aquila Biomedical acquired by Concept Life Sciences |
| Organisation | Concept Life Sciences |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Aquila Biomedical was acquired by Concept Life Sciences in October 2017. Since February 2018 Concept Life Sciences has been part of Spectris plc, a FTSE250 company. Aquila Biomedical employs 30 members of staff and generated £3.8m revenue in 2018. It is anticipated that a £5m+ turnover and an increase in staff numbers to around 50 will be achieved by 2020. |
| Collaborator Contribution | The acquisition will progress the company in turnover, number of staff, resources etc. |
| Impact | One of the first CROs to be built from an immunology base and one of the first to offer immune-oncology services. Outcome from the acquisition should result in higher £ turnover and increase in staff numbers. No other CRO offered such a broad range of assays in the immuno-oncology service or had an assay which could measure reversal of T cell exhaustion. |
| Start Year | 2017 |
| Description | Edinburgh Partners Devices and Diagnostics |
| Organisation | Heriot-Watt University |
| Department | School of Engineering & Physical Sciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | University of Edinburgh led a collaboration with Heriot-Watt that includes Confidence in Concept funding covering Devices Diagnostics and Diagnostics Apps for hand help devices. Edinburgh brings the medical and unmet need and computing aspects through School of Informatics. |
| Collaborator Contribution | Heriot Watt brings proven engineering and fabrication skills/ capabilities applied to medical devices |
| Impact | The outputs are listed under MC_PC_12014 We have expanded the collaboration beyond the funded projects in MC_PC_12014 into a project on birthing mirror and a histology water bath. We have combined with Heriot Watt to bring together a further CiC application in October 2014 |
| Start Year | 2012 |
| Description | Fibromed with Institute of Cancer Research |
| Organisation | Institute of Cancer Research UK |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Scientists are providing stem cell hepatocytes |
| Collaborator Contribution | The pharmacology group are characterising the performance of these cells against the gold standard primary human hepatocytes |
| Impact | Data on optimisation of the product |
| Start Year | 2013 |
| Description | NHS Lothian |
| Organisation | NHS Lothian |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | We are building on the model developed by the Translational Entrepreneur appointment with the College of Medicine & Vet Medicine, working in collaboration to enhance technology transfer from University of Edinburgh and NHS Lothian |
| Collaborator Contribution | Funding of an Enterprise Associate position to work with the Translational Entrepreneur and team towards extending our area of operation to build understanding, help culture change and deliver commercial outputs for NHS Lothian |
| Impact | With NHS Lothian, the Entrepreneur set up a parallel system to the one he ran in the University. This is now formally part of the Edinburgh BioQuarter. NHS Lothian have paid for a post, a Business dev exec, to follow mentoring through the EiR and bus. dev manager and adopt the process of working with PIs to address unmet needs by developing imaginative yet milestone driven projects & programmes, building teams, taking advantage of industry contacts and delivering products and services that meet these unmet needs. The associate continues to build translational projects with one not for profit company formed ipSOX www.ipsox.co.uk by 2 nurses and a consultant from the metabolic unit to provide bespoke covers for insulin pumps. ipSOX has been formed from NHS Lothian and Napier University and collaborates extensively with a UK company on design and manufacture of covers that already are achieving exports and significant orders through users and manufactures. We are using this company to train an intern, who is delivering new media communication as part of diabetes month with "memorable diabetes momments" to expand marketing reach. This is an example of harnessing enthusiastic professionals into a non conventional translational delivery approach that has alrady donated to diabetes research and is building new products for pump users and will shortly be applying profits to fund insulin pump research applications. The brand is being transferred to a company producing insulin pen covers http://pentrim.com/ who will continue the supply to customers, donating profits to JDRF and developing the sports range. The Business Development Executive continues to build multiple translational projects for the NHS and has accessed valuable sources of funds to provide catalytic investment into projects. |
| Start Year | 2009 |
| Description | ipSOX Funky Fone Sox |
| Organisation | Funky Fone Sox Company |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The ipSOX team designed the products to be manufactured |
| Collaborator Contribution | Funky Fone Sox organised the manufacturing of the ipSOX insulin pump covers at no added cost |
| Impact | Donations made to Diabetes UK |
| Start Year | 2011 |
| Title | MBP Tracker Mouse |
| Description | MBP-Tracker technology allows us to specifically follow those T cells that drive pathology, quantify them in different organs (including the CNS) and to measure the activation of a range of key disease-associated functions within these T cells |
| IP Reference | |
| Protection | Protection not required |
| Year Protection Granted | |
| Licensed | Yes |
| Impact | Aquila BioMedical is using the technology in industrial collaborations on multiple sclerosis drug discovery projects |
| Title | Aquila Biomedical venture |
| Description | Aquila biomedical was incorporated as a company late 2011. Aquila is a preclinical services venture specilaising in turning high-end biological assays (assays based on advanced molecular understanding of disease processes) into screening tools for drug candidate selection. We started in MS with novel MOA models for demyelination and remyelination. The company has expanded more broadly in autoimmunity added pain including cancer pain. Plan to move to other areas - cancer and inflammation and human cell models. This venture has broad support in the University. Now established, it is providing a mechanism for efficient use of many academic assets that are currently underutilised for commercial purposes. The business team has been built and investment obtained and now the company is fully operation and in addition to offering services is building new MOA models. |
| Type | Support Tool - For Fundamental Research |
| Current Stage Of Development | Small-scale adoption |
| Year Development Stage Completed | 2010 |
| Development Status | Actively seeking support |
| Impact | Company formed, 2x SMART award recieved and 3 employees actively validating models in auto immune MS and pain. aquila-bm.com Now building MS in a dish model with license of specialist mouse line from DKFZ |
| URL | http://www.aquila-bm.com |
| Title | Clinical Imaging Services venture |
| Description | Under development through our extension to NHS with appointed BDE now 3 year in post. Concept to capitalise on collective imaging capabilities in various areas ( neuroscience, heart, lung) into a clinical services company. Currently academics do a level of service work that is beneficial though eats time and is not capitalised on fully by the University/NHS. Using the translator's connections to build business team and generate a company. This is an outcome that the clinicians have asked for help in developing. A company vehicle will improve revenue directly back to the core facility that already does a level of contract work with industry but loses its income to a broad University pot. With a business/sales team we expect to increase hugely demand and exposure and hire dedicated staff. The University will benefit from this exposure but also directly financially through consultancy arrangements and as a shareholder. |
| Type | Diagnostic Tool - Imaging |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2010 |
| Development Status | Closed |
| Impact | was developed as consultancy |
| Title | Clinical Lab services |
| Description | This opportunity is being developed under our new line of activity with the NHS and our BDE appointed, now 1 year as an FTE. Development of NHS resources from a testing (receivership) based model to an organisation capable of capitalising on its inherent assets (strategic & proactive, business orientated) - particularly it's combination of speed and expertise to develop new assays for disease (worldwide flu variants good example), and its expertise in pathology. Two approaches are being developed. One is an extension of core services. Second is a vehicle through which the NHS can build strategic alliances through Translator connections to companies (eg: Sequenom and HistoRx) and expertise (eg: Prof Chris Price) |
| Type | Management of Diseases and Conditions |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2010 |
| Development Status | Closed |
| Impact | impact to be realised. Process too early at present. Hope to be first EU site for novel genetic tests for selection of patients for wet MD. Further tests under discussion with major US molecular analysis innovator. |
| Title | Cognition product 1 - AD test |
| Description | this is a laptop based test for AD based on dual task responses and their interpretation. The algorithms have been refined based on over 30 years research (Bob Logie, de laSalla) . We have aligned with Toshiba to help us in the future access worldwide markets. At present we are seeking funds to further validate and refine the test in ongoing large clinical trials. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2010 |
| Development Status | Actively seeking support |
| Impact | This will be commercialised for sale in the US and EU, have revenues generated for the University and funders ( along with normal T&Cs). |
| Title | Fibromed Products |
| Description | A company based on a combination of stem cell science ( hepatocytes generated through iPS) and a novel polymer support (for differentiation & growth) to be used as a screening tool for pharma in selecting against hERG channel activators, metabolic breakdown products, or patients likely to adversely react in trials. Once hepatocyte established, Fibromed may develop complementary areas (eg: cardiomyocyte screening). |
| Type | Support Tool - For Medical Intervention |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2012 |
| Development Status | Actively seeking support |
| Impact | Company has been formed (fibromed.co.uk) with 3 leading accademics and HM. Biobank of phenotyped and genotyped cells for iPS development is under construction working with hospitals and Generation Scotland biobank. Hepatocytes are being validate by industry collaborations. Two Executives are retained under HGU funding |
| URL | http://www.fibromed.co.uk |
| Title | Insulin pump holder |
| Description | This opportunity has been developed under our activity with the NHS and our BDE appointed, now 2 year in as mentioned in 'collaborations' section. We are developing a soft, flexible cover for diabetes monitors to suit patients needs. We are doing this with a company called ' Funky phone Sox'. We have established a NFP to deal with proceeds that will be donated back to the Metabolic Unit in Edinburgh |
| Type | Support Tool - For Medical Intervention |
| Current Stage Of Development | Small-scale adoption |
| Year Development Stage Completed | 2010 |
| Development Status | Under active development/distribution |
| Impact | A good example of how an unmet need that patients and staff have identified is being translated to a product through with NHS savings through innovation can be realised, with determination on development and imagination on proposing a NFP. This is also an example of an opportunity that despite being valuable and with a significant element of 'culture change' attached to the outcome, might otherwise not be developed as it does not fit with typical TTO metrics (eg: disclosure, patent, licensable). Translator connections include materials experts to adapt current form and media and governance support. |
| URL | http://www.ipsox.co.uk |
| Title | Speckled Computing - solutions for e-health |
| Description | This opportunity is being developed under our new line of activity with the NHS and our BDE appointed, now 3 year in post. Speckled computing has telehealth applications in movement based monitoring in the home and in ITUs or wards. This is a multi healthcare application based technology involving major multidisciplinary teams. Our BDE with translator guidance runs teams that cross medicine, infomatics and support services (edinburgh clinical trials and statistics) as well as company collaborators. There are at least 4 applications. Two (COPD and post operative care) are teams actively seeking funds ( HICF - through to round 2) and pertners. Phillips and Tunstall are connections made through the MRC translator. The Tunstall collaboration is part of a 1.5m HICF application presently through to round 2 assessment. |
| Type | Management of Diseases and Conditions |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2010 |
| Development Status | Actively seeking support |
| Impact | notable company collaborations and multiple funding applications. Too early for health impact. |
| Title | chronic pain treatment |
| Description | Agonist for TRPM8 as topical treatment for chronic pain funded by SE POC. New funding warded for 6 month chemistry programme from Edinburgh bioQuarter - bridge funding for continuation and talent retention. Now complete 2010. New funding for full team July 2010 from MRC pilot portfolio award. In progress through to end in 2011 |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2009 |
| Development Status | Under active development/distribution |
| Impact | in advanced discussion with Pharma |
| Title | chronic pain treatment 2 |
| Description | we are developing a reformulation of an existing drug used as currently as an adjuvant treatment for chronic neuropathic pain experienced by cancer patients. A phase III is currently running with an oral capsule formulation. Currently in paractive this drug is taken intramuscularly or in liquid oral form. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2010 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | We seek to develop this first as a special and later in other more refined oral liquid capsules rather than the loose filled powder capsule currently in trial. This could bring revenue to the University and a spin out company and encourage other clinicians to think about IP that is contained within their studies. This type of IP is not typically developed by institutes, as it would be pre-selected against due to the development work required and it's non patentable nature. |
| URL | https://clinicaltrials.gov/show/NCT01316744 |
| Title | chronic pain treatment 3 |
| Description | An open label study with a well known and available compound has been completed. The study looked at a variety of cancer drug induced pain patients and their response. The compound is now seeking funds for an efficacy study. It will in parallel be developed as a specials product and later be incorporated into new topical formulations (gel, patch, spray) |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2010 |
| Development Status | Under active development/distribution |
| Impact | This could bring revenue to the University and a spin out company and encourage other clinicians to think about IP that is contained within their studies. |
| Company Name | Aquila Biomedical Ltd |
| Description | Aquila Biomedical is a research service company with strong links to the University. http://www.aquila-bm.com |
| Year Established | 2011 |
| Impact | Company formed, 2 SMART awards received and 20 employees actively validating models in auto immune MS and pain with pharmaceutical contracts in place. Global client base US, EU and Japan Pharma and Biotech. Company now delivering immuno-oncology models for drug discovery. Formed an LLP Aquila Histoplex to provide advanced histology. SO304736. Due to success this LLP is now being incorporated as a division of Aquila http://histoplex.co.uk/ Aquila is now trading profitably and is scheduled to be at 30 employees in early 2018. |
| Website | http://www.aquila-bm.com/index.html |
| Company Name | Fibromed Products Ltd |
| Description | Company has been formed (fibromed.co.uk) with 3 leading accademics and HM. Biobank of phenotyped and genotyped cells for iPS development is under construction working with hospitals and Generation Scotland biobank. Hepatocytes are being validate by industry collaborations. http://www.fibromed.co.uk. The company was wound up in 2015 due to failure to close investment round. |
| Year Established | 2013 |
| Impact | Agreements with Generation Scotland, Roslin Cells and University will underpin the growth of the company. Fibromed Product was formed from Fibromed Ltd launched in 2011. The companies hepatocyte system was described by Oliver Flint of BMS as the best available for testing hepatotoxic liabilities of drug molecules. |
| Website | http://www.fibromed.co.uk/ |
| Company Name | ipSOX ltd |
| Description | www.ipsox.co.uk ipSOX covers for insulin pumps come in a selection of colours and designs that stretch to fit your insulin pump. All ipSOX profits are reinvested to support diabetes care. |
| Year Established | 2011 |
| Impact | Provided over 20000 covers and is currently designing products for use in sporting activities. |
| Website | http://www.ipsox.co.uk |
| Company Name | NeurocentRx Pharma |
| Description | www.neurocentrx.com The company is focussed on building a platform of products for treatment of chronic neuropathic pain and will be launched its first product as specials in 2015. The product is being supplied based on hospital request across the UK. The topical product uses menthol a natural agonist of TRPM8 that has been demonstrated in a 50 patient trial to be effective in cancer treatment induced neuropathic pain. NeurocentRx has licensed a University patent for the use of menthol in this indication that is now granted in Europe. NeurocentRx Pharma has also licensed the data from a large clinical trial on oral ketamine as will examine the data for potential support of a regulatory study when the study reports. |
| Year Established | 2013 |
| Impact | The company has raised over £500,000 seed investment and grants. |
| Website | http://www.neurocentrx.com/ |
| Description | BIO International US meeting - BIO Partnering |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Business Partnering Forum for Pharma / Biotech and CROs. Seeking opportunities for company propositions. Potential future clients for BioQuarter development. Potential future company partners . |
| Year(s) Of Engagement Activity | 2008,2009,2010 |
| Description | BIO business - Geneva 2008 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Platform shared with Roche on innovative company spin-out plans for a CNS company. none yet |
| Year(s) Of Engagement Activity | 2008 |
| Description | BioDundee conference 2010 -chair of panel on Building Alliances |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | chair of panel that focused on partnerships and collaborations within the life science sector. event focused on science-business community including life science entrepreneurs engagement of VC interest for bioQUarter, alliance forged with inward investment company for new venture, partnerships for translational programmes in NHS and the University |
| Year(s) Of Engagement Activity | 2010 |
| Description | Biotrinity Investor conference Fibromed |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | Yes |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | One of UK largest investor conferences, presenting to more than 100 investors. Engagement with investors and Pharma executives |
| Year(s) Of Engagement Activity | 2012 |
| Description | Commercialisation Seminar |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | Yes |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | The entrepreneur in residence and effect on spin-out activity. Proof of Concept Programme Symposium on creating high value spin-outs: Glasgow Connections made to senior business and academic colleagues |
| Year(s) Of Engagement Activity | 2008 |
| Description | Commercialisation seminar |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Participants in your research and patient groups |
| Results and Impact | Presented in seminar on commercialisation Division of Pathway Medicine University of Edinburgh Interest in translational activity. Measured by two subsequent DPFS Portfolio applications |
| Year(s) Of Engagement Activity | 2007 |
| Description | Conference For Generation Scotland |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | Yes |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Health professionals |
| Results and Impact | Academic and Pharma executive exploring how to use biobanks continued engagement on use of Generation Scotland for generation of specific iPS lines for toxicity testing |
| Year(s) Of Engagement Activity | 2012 |
| Description | Conference Panel |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | Yes |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Mixed audience of Pharma and Biotech executives -who engaged in the discussion on the changes in the drug development industry and how to best access expertise from accademia Follow up with several companies |
| Year(s) Of Engagement Activity | 2011 |
| Description | Globalscot Meeting Hong Kong |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | Yes |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Presentation on Scottish Life Science at globalscot meeting Hong Kong. December 2008 meeting with influential international business people and investors, initiated concept of incubator fund |
| Year(s) Of Engagement Activity | 2008 |
| Description | Globalscot Meeting New York |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | Yes |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Workshop on Scottish Life Science at globalscot meeting New York. December 2007. Recognition of opportunity and issues by this influential group |
| Year(s) Of Engagement Activity | 2007 |
| Description | Investor Meeting Fibromed |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | Yes |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Approximately 50 investors were present for the event. Engagement with 2 investors was initiated. Fibromed was invited to present at BioTrinity 2012 |
| Year(s) Of Engagement Activity | 2011 |
| Description | Judge on Venture Competition |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | Yes |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | Local |
| Primary Audience | Undergraduate students |
| Results and Impact | Finals of Dundee Students Venture competition to award £10,000 in prize money continue to engage with the Design aid+ team on accessories for junior doctors |
| Year(s) Of Engagement Activity | 2012 |
| Description | Judge on Venture Competition |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | Yes |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | Regional |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | Finals of Dundee Students Venture competition. Presentations questions and award Trias Gkikopoulos has been named the winner of the University of Dundee's Venture 2013 competition for his business idea of designing and building an unmanned aircraft for civil, commercial and scientific use. National press. |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://www.dundee.ac.uk/pressreleases/2013/march13/ventureprize.htm |
| Description | Medical Training on Pharmaceutical Product Development |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | Yes |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Health professionals |
| Results and Impact | Invited speaker to put the drug industry in context Engagement from a Glasgow Doctor on commercial options |
| Year(s) Of Engagement Activity | 2012 |
| Description | UNICO |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | Yes |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Entrepreneurs in residence: strangers in our midst? UNICO CONFERENCE Nottingham - 5-7 December 2007 Continued support from Scottish Enterprise |
| Year(s) Of Engagement Activity | 2007 |